Publications & Posters

Scientific Publications and Posters

We continue to validate, strengthen and leverage our single-cell platform with world leaders and pioneers in immunology and cancer research. Our high scientific standards have been validated in numerous peer-reviewed publications and conference presentations.

HFB9-2, a novel Galectin-9 neutralizing antibody to reverse immune suppression in the tumor microenvironment

Presenters: Roshan Kumar, PhD, Senior Director, Head of Discovery Biology and US External Innovation and Yun-Yueh Lu, PhD, Project Leader, Principal Scientist, Disease Biology HFB2009 program focuses on developing anti-Gal-9 neutralizing antibodies as a potential first-in-class treatment for AML and solid tumors, both as a single agent and a combination therapy. More information about these … Continued

Discovery and characterization of novel TNFR2 antibodies to modulate T cell activities in immunosuppressive environment

Presenters: Francisco Adrian, PhD, Senior Vice President, Head of Research and Shuo Wei, PhD, Project Leader, Principal Scientist, Disease Biology HFB200301 is an anti-TNFR2 monoclonal antibody being developed as a potential first-in-class therapeutic for the treatment of biomarker-selected patients with advanced cancer. More information about these and other programs in the HiFiBiO Therapeutics pipeline is … Continued

HFB301001, a novel OX40 agonistic antibody with a unique pharmacological profile and innovative biomarker strategy

Presenters: Andreas Raue, PhD, Project Leader, Senior Director, Head of Drug Intelligent Science (DIS™) at HiFiBiO Therapeutics and Robert Petit, PhD, Senior Scientific Advisor HFB301001 is being developed as a potential novel treatment option for cancer coupled with a patient stratification biomarker in solid tumor indications. More information about these and other programs in the … Continued

High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics

Mining the antibody repertoire of plasma cells and plasmablasts could enable the discovery of useful antibodies for therapeutic or research purposes1.

HiFiBiO Therapeutics and Leading Academic Institutions Demonstrate Breakthrough Single-Cell Approach for Novel Biomarker Discovery to Combat Cancer

The Nature Genetics publication describes a novel high-throughput single-cell ChIP-seq approach to studying heterogeneity of chromatin states within complex biological systems. Our proprietary single-cell CelliGO platform and unique DIS capabilities were used to probe why certain disease cells are resistant to available therapeutics.

Shared Insights About Guiding Principles of Open Collaboration in Drug Discovery Today From HiFiBiO CEO Liang Schweizer and COO Jeff He

Guiding principles of value creation through collaborative innovation in pharmaceutical research HiFiBiO CEO Liang Schweizer and COO Jeff He outline the importance of breaking down common barriers in collaborations, propose four guiding principles for such co-operation and offer a framework to reach value inflection points quicker.

Single-Cell Deep Phenotyping of lgG-Secreting Cells for High-Resolution Immune Monitoring

The Nature Biotechnology manuscript details DropMap, “a powerful and elegant technology for the phenotypic analysis of antibody-secreting cells (ASCs) at the single-cell level with unprecedented throughput and resolution.” This droplet microfluidics approach was developed with collaborators from ESPCI and Institut Pasteur.

Antibody Discovery by Deep Mining of Immune Repertoires

Antibody Discovery by Deep Mining of Immune Repertoires: A demonstration of the HiFiBiO CelliGO™ Platform versatility and robustness with Tetanus Toxoid antigen as a case study